On 23 Oct 2023, the updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer was reported at the ESMO Congress.

The disclosure of the clinical trial of Trastuzumab deruxtecan (T-DXd) for the pretreatment of patients (pts) with her2-expressing solid tumors at ESMO 2023 provides the factual basis for subsequent, more in-depth studies.

On 23 Oct 2023, the clinical results of Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1% was reported at the ESMO Congress.

The clinical trial for Capmatinib Hydrochloride took center stage at the 2023 ESMO Congress, demonstrating its potential to treat aNSCLC.

Atezolizumab plus bevacizumab (AB) is a frequent first-line treatment for advanced hepatocellular carcinoma (HCC), shown superior to sorafenib in the IMbrave150 trial. On October 20, 2023, an Atezolizumab trial was presented at the ESMO Congress.

The ESMO Congress presented a summary of the RATIONALE-315 phase III trial: Neoadjuvant tislelizumab plus platinum-based chemotherapy showed a pathological response in operable stage II-IIIA NSCLC, prompting detailed trial result discussions.

On 23 Oct 2023, liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib was reported at the ESMO Congress.

The 2023 ESMO Congress marked a pivotal moment with the disclosure of a clinical trial for Osimertinib mesylate in EGFR-mutated NSCLC patients, opening avenues for further increases in its clinical efficacy.

The recent ESMO Congress presented noteworthy clinical trial results of Givastomig, paving the way for a detailed exploration of its therapeutic potential in solid tumors.

On 23 Oct 2023, GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) was reported at the ESMO Congress.

On 23 Oct 2023, the phase Ib/II clinical trial result of Cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma was reported at the ESMO Congress.

Sunvozertinib (DZD9008) is a targeted, irreversible EGFR inhibitor selective for EGFR mutations. Initial findings for sunvozertinib in treating naïve EGFR exon20ins NSCLC were presented at the ESMO Congress.